HACKENSACK, N.J. -- A new drug shown to prolong the lives of women who have metastatic breast cancer has been approved by the Food and Drug Administration.
Halaven, a new injection treatment synthetically created based on a sea sponge, was developed by Woodcliff Lake-N.J.-based Eisai Inc. 5/8In a multicenter study of 762 patients, those taking the drug lived a median of 2.5 months longer than those not given the medicine. Overall survival was slightly 5/8more than 13 months, compared with 10 1/2 months for those who did not receive it.
The FDA approved Halaven for patients with metastatic breast cancer who have previously undergone at least two chemotherapy treatments for early or advanced breast cancer. The drug binds to the proteins that help cells divide, slowing the progression of the disease.